1. Finland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Orion Oyj

Orion Oyj

ORNBV.HE
Orion OyjFI flagNASDAQ Helsinki
71.90
EUR
+1.40
- -
10.12BMarket Cap
Orion Oyj
ORNBV.HE
(NASDAQ Helsinki)

Recent

price

71.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6.03
6.52
6.96
7.14
7.22
7.21
7.63
7.35
6.95
7.48
7.67
7.41
9.54
8.48
10.98
13.43
11.92
Revenue per Share
1.31
1.49
1.47
1.46
1.5
1.48
1.77
1.61
2.35
1.43
1.57
1.38
2.49
1.54
2.35
3.56
2.69
Basic EPS, GAAP
1.23
1.09
1.22
1.01
1.71
1.5
1.43
1.08
1.17
1.67
1.84
0.93
2.57
0.02
1.47
1.56
1.55
Free Cash Flow per Basic Share
1.1
1.26
1.42
1.3
1.25
1.3
1.31
1.55
1.45
1.5
1.5
1.5
1.5
1.6
1.62
1.64
1.63
Dividend per Share
3.12
3.42
3.61
3.63
3.61
4.17
4.54
4.81
5.47
5.53
5.6
5.49
6.5
6.43
7.19
9.13
6.54
Book Value per Share
2.73
2.95
3.08
3.14
3.21
3.82
4.18
4.46
5.04
5.18
4.9
4.83
5.1
4.92
5.91
7.8
5.22
Tangible Book Value per Share
141
141
141
141
141
141
141
141
141
141
141
141
141
140
140
141
141
Basic Weighted Avg Shares
850
918
980
1,007
1,015
1,016
1,074
1,034
978
1,051
1,078
1,041
1,341
1,190
1,542
1,890
1,677
Sales/Revenue/Turnover
29.91
30.66
28.32
26.27
26.75
26.36
27.22
27.44
25.69
23.94
25.64
22.83
32.54
22.29
26.88
33.29
28.46
Operating Margin (%)
39
42
40
38
40
42
41
42
42
56
56
46
48
52
93
57
- -
Depreciation Expense
185
210
207
206
211
208
249
226
330
200
220
194
350
217
330
500
378
Net Income, GAAP
26.88
25.67
25.2
21.89
21.14
20.66
19.91
21.1
20.53
20.14
20.98
20.02
20.62
20.26
20.14
20.31
20.18
Effective Tax Rate (%)
21.73
22.82
21.11
20.48
20.81
20.5
23.19
21.87
33.79
19.07
20.4
18.62
26.07
18.22
21.39
26.48
22.54
Profit Margin (%)
292
290
337
432
438
441
461
441
414
412
530
481
603
561
742
784
467
Working Capital
88
66
107
233
210
178
150
150
1
7
106
105
197
171
297
115
136
LT Debt
467
500
510
514
515
595
641
680
773
779
731
748
908
890
1,005
1,284
920
Total Equity
31.95
35.3
33.25
28.94
28.11
27.68
29.49
27.33
22.6
23.26
26.58
22.16
34.67
18.9
26.92
33.32
33.47
Return on Invested Capital (%)
35.05
37.71
34.37
29.6
28.51
27.97
32.26
28.35
38.16
23.67
26.23
21.93
34.95
19.82
27.54
34.62
33.34
Return on Capital (%)
44.12
45.5
41.8
40.43
41.42
37.99
40.61
34.36
45.65
25.9
28.13
24.89
41.5
23.88
34.5
43.6
44.71
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
30
30
182
LT Borrowings
291
- -
- -
LT Finance Leases
6
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
141
141
141
Market Capitalization
6,023
7,726
8,980

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,016
1,084
1,008
Cash, Cash Equivalents & STI
206
259
184
Accounts Receivable, Net
255
288
252
Inventories
419
433
442
Total Current Liabilities
274
278
541
Payables & Accruals
- -
- -
- -
ST Debt
30
30
182
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.46%
12.49%
27.81%
Free Cash Flow
935.18%
1,864.03%
6.15%
Net Income, GAAP
16.12%
26.86%
51.65%
Sales/Revenue/Turnover
7.29%
13.25%
22.5%
Total Cash Common Dividend
- -
- -
1.36%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
308
328
471
434
1,542
2025
355
416
695
- -
1,890
2026
418
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.31
0.37
1.14
0.52
2.35
2025
0.44
0.59
1.85
- -
3.56
2026
0.64
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.81
- -
0.81
1.62
2025
- -
0.83
0.82
- -
1.64
2026
- -
- -
- -
- -
- -
Similar Companies
Astellas Pharma Inc. (4503.T)
Otsuka Holdings Co., Ltd. (4578.T)
Ono Pharmaceutical Co., Ltd. (4528.T)
GSK plc (GS7.DE)
Pfizer Inc. (PFE)
GSK plc (GSK.L)
Business
Orion Oyj develops, manufactures and markets human pharmaceuticals, veterinary pharmaceuticals and active pharmaceutical ingredients for global markets; its core therapy areas encompass central nervous system disorders including Parkinson's disease treatments such as Entacapone, Stalevo, Comtess and Comtan, oncology products like Nubeqa for prostate cancer and Fareston for breast cancer, respiratory medications including inhaled Easyhaler pulmonary drugs, as well as pain management with Burana, cardiovascular treatments like Simdax, hormone therapies such as Divina series for menopausal symptoms, and veterinary drugs including Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo and Tessie; the company also provides contract manufacturing services for various dosage forms encompassing tablets, capsules, liquids, semi-solids, hormonals, small volume parenterals and cytostatics, alongside diagnostic tests and APIs for generic and proprietary compounds. Founded in 1917 and headquartered in Espoo, Finland, Orion Oyj operates primarily from manufacturing and R&D sites in Finland, with its own sales organizations covering key European markets, Scandinavia, North America and select Southeast Asian countries, while products reach over 100 countries through partners; customers include specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, laboratories and pet owners. In recent developments, Orion Oyj secured an exclusive commercial license in October 2025 from Abzena for a monoclonal antibody targeting a high unmet-need cancer to bolster its oncology pipeline, received a EUR 180 million milestone payment from Bayer related to Nubeqa sales as announced on December 3, 2025 alongside an upgraded full-year 2025 outlook, earned the Republic of Finland President's international growth award in the growth company category in November 2025, and reported continued strong net sales growth in its January-September 2025 interim results despite a phase 2 study setback for insomnia drug ODM-105.